{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-033173","form_type":"8-K","ticker":"PPCB","cik":"0001517681","company_name":"Propanc Biopharma, Inc.","filed_at":"2026-07-14T20:01:28+00:00","discovered_at":"2026-07-14T20:02:56.174773+00:00","generated_at":"2026-07-14T20:03:02.289436+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Propanc Biopharma appoints Carlo Campiciano to Board, replacing retiring director Annie Van Broekhoven","bullets":["Annie Van Broekhoven retired from Board effective July 8, 2026.","Carlo Campiciano appointed to fill vacancy; he is a qualified accountant and former CFO of MedAdvisor.","Director agreement provides $45,000 annual cash compensation paid quarterly.","Equity compensation of 0.5% to 4.99% based on milestone achievements.","Campiciano is independent per Nasdaq/NYSE American standards."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-033173","json":"https://secwatch.observer/filing/0001493152-26-033173.json","markdown":"https://secwatch.observer/filing/0001493152-26-033173.md","text":"https://secwatch.observer/filing/0001493152-26-033173.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517681/000149315226033173/0001493152-26-033173-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517681/000149315226033173/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-14T20:03:02.289436+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}